

	Cohort 1 6 	Cohort 2 5 	Cohort 3 8 	Cohort 4 15 
Efgartigimod dose (mg/kg)	10			
Induction	4 Weekly infusions			
Maintenance period (weeks)	6	8	12	Up to 34
Maintenance Dosing	2 doses at weeks 2 and 6	Every other week		
Associated prednisone	No steroids or stable dose of prednisone (patients relapsing on therapy)	Discretion of investigator (monotherapy or 20 mg/d)		
	20 mg/d (patients off therapy) or stable dose (patients on therapy)			

Fig. 1




Fig. 2




Fig. 3




Fig. 4A




Fig. 4B




Fig. 4C




Fig. 4D




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D




Fig. 6A




Fig. 6B




Fig. 6C




Fig. 6D




Fig. 6E




Fig. 7A




Fig. 7B




Fig. 8A




Fig. 8B




Fig. 9A




Fig. 9B




Fig. 10A




Fig. 10B




Fig. 11A




Fig. 11B




Fig. 11C




Fig. 11D




Fig. 11F




Fig. 11E




Fig. 11H




Fig. 11G

Fig. 12C





Fig. 12D

Fig. 12A





Fig. 12B




Fig. 13




Fig. 14